Antibody–drug conjugates for cancer: poised to deliver?
2010
Highlighted by Genentech's recent US regulatory submission for trastuzumab–DM1, antibody–drug conjugation technology could be heading for the mainstream in anticancer drug development.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
142
Citations
NaN
KQI